Department of Microbiology, Ajou University School of Medicine, Suwon 16499, Republic of Korea.
Department of Biomedical Sciences, Graduate School of Ajou University, Suwon 16499, Republic of Korea.
Int J Mol Sci. 2024 Aug 20;25(16):9018. doi: 10.3390/ijms25169018.
The NACHT-, leucine-rich-repeat-, and pyrin domain-containing protein 3 (NLRP3) is a critical intracellular sensor of the innate immune system that detects various pathogen- and danger-associated molecular patterns, leading to the assembly of the NLRP3 inflammasome and release of interleukin (IL) 1β and IL-18. However, the abnormal activation of the NLRP3 inflammasome has been implicated in the pathogenesis of autoinflammatory diseases such as cryopyrin-associated autoinflammatory syndromes (CAPS) and common diseases such as Alzheimer's disease and asthma. Recent studies have revealed that pyrin functions as an indirect sensor, similar to the plant guard system, and is regulated by binding to inhibitory 14-3-3 proteins. Upon activation, pyrin transitions to its active form. NLRP3 is predicted to follow a similar regulatory mechanism and maintain its inactive form in the cage model, as it also acts as an indirect sensor. Additionally, newly developed NLRP3 inhibitors have been found to inhibit NLRP3 activity by stabilizing its inactive form. Most studies and reviews on NLRP3 have focused on the activation of the NLRP3 inflammasome. This review highlights the molecular mechanisms that regulate NLRP3 in its resting state, and discusses how targeting this inhibitory mechanism can lead to novel therapeutic strategies for NLRP3-related diseases.
NACHT、富含亮氨酸重复序列和pyrin 结构域蛋白 3(NLRP3)是先天免疫系统的关键细胞内传感器,可检测各种病原体和危险相关的分子模式,导致 NLRP3 炎性小体的组装和白细胞介素(IL)1β和 IL-18 的释放。然而,NLRP3 炎性小体的异常激活与自身炎症性疾病(如 cryopyrin 相关自身炎症综合征(CAPS))和常见疾病(如阿尔茨海默病和哮喘)的发病机制有关。最近的研究表明,pyrin 作为一种间接传感器发挥作用,类似于植物的保护系统,并通过与抑制性 14-3-3 蛋白结合而受到调节。激活后,pyrin 转变为其活性形式。NLRP3 预计遵循类似的调节机制,并在笼模型中保持其无活性形式,因为它也作为间接传感器起作用。此外,新开发的 NLRP3 抑制剂已被发现通过稳定其无活性形式来抑制 NLRP3 活性。大多数关于 NLRP3 的研究和综述都集中在 NLRP3 炎性小体的激活上。这篇综述强调了调节 NLRP3 处于静止状态的分子机制,并讨论了靶向这种抑制机制如何为 NLRP3 相关疾病带来新的治疗策略。